The amended claims expand the scope of protection of the Company's technology to include not only the core mucoadhesive composition, but also drug delivery systems and methods of use, which are designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. This development aligns with the Company's strategy to strengthen its global intellectual property portfolio.
The expanded claims relate to compositions comprising sulfated polysaccharide polymers and additional polymeric components that form a uniform and continuous film upon contact with epithelial mucosa, enabling improved delivery of active pharmaceutical ingredients (APIs).
Key Potential Features of the Platform:
- Prolonged Residence Time: Enhancing the duration that drugs remain at the site of administration, supporting improved absorption and efficacy.
- Improved Bioavailability: Increasing the effectiveness of APIs through enhanced mucosal interaction and retention.
- Controlled Film Formation: Transformation into a uniform, continuous film upon contact with mucosal surfaces.
- Versatility: Compatibility with a wide range of drug types and therapeutic indications.